Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07358546 · ClinicalTrials.gov registry record · Phase 1
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
A Phase 1 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07358546 is a Phase 1 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 32 participants.
The verdict
NCT07358546, a Phase 1 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.
Interventions
- DRUG Efimosfermin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-03-13 |
| Est. Completion | 2027-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07358546
The ClinicalTrials.gov registry entry for NCT07358546 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Efimosfermin alfa is the first listed.
NCT07358546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07358546 about?
NCT07358546 is a clinical study titled "A Study of Efimosfermin Alfa in Adults With Hepatic Impairment". This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.
What is the current status of trial NCT07358546?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-03-13. Estimated completion is 2027-10-13.
What interventions are being tested in trial NCT07358546?
The interventions under investigation include: Efimosfermin alfa (DRUG).
Who is sponsoring clinical trial NCT07358546?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.